Q3 2025 Taysha Gene Therapies Inc Earnings Call Transcript
Key Points
- Taysha Gene Therapies Inc (TSHA) received FDA breakthrough therapy designation for TSHA-102, highlighting its potential to redefine treatment for Rett syndrome.
- The company has achieved regulatory clarity and alignment with the FDA on the Revealed Pivotal Trial Protocol and Statistical Analysis Plan, supporting their planned BLA submission.
- TSHA-102 demonstrated a 100% response rate in Part A of the Reveal trials, with patients achieving developmental milestones.
- The company regained full global rights to the TSHA-102 Rett Syndrome Program, providing strategic flexibility.
- Taysha Gene Therapies Inc (TSHA) has a strong balance sheet with $297.3 million in cash and cash equivalents, expected to support operations into 2028.
- Research and development expenses increased significantly to $25.7 million for the quarter, driven by manufacturing initiatives and higher compensation expenses.
- The company reported a net loss of $32.7 million for the quarter, an increase from the previous year's loss.
- General and administrative expenses rose to $8.3 million, partly due to debt issuance costs.
- The pivotal trial requires enrolling 15 patients, and while demand is high, the timeline for full enrollment could extend up to six months.
- There is a need for ongoing dialogue with the FDA regarding the inclusion of younger patients in the BLA submission, which could impact timelines.
Good day, everyone, and welcome to the Taysha Gene Therapies' third quarter 2025 earnings call. (Operator Instructions) Please note this call may be recorded, and I will be standing by if you should need any assistance. It is now my pleasure to turn the conference over to Haley Collins. Please go ahead.
Thank you. Good morning, and welcome to our third quarter 2025 financial results and corporate update call. Earlier today, Taysha issued a press release announcing financial results for the third quarter ended September 30, 2025. A copy of this press release is available on the company's website and through our SEC filing. Joining me on today's call are Sean Nolan, Taysha's Chief Executive Officer; Sukumar Nagendran, President and Head of R&D; and Kamran Alam, Chief Financial Officer.
We will hold a question-and-answer session following our prepared remarks. On today's call, we will be making forward-looking statements, including
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
